Excellence in clinical research from A to Z

Scroll down ⇩

About us

AtoZ-CRO GmbH is a full-service clinical research organisation (CRO) located in Overath near Cologne, Germany, with over 30 years of experience in clinical development and clinical study management. As a specialist for Germany, Europe, the US, and India, AtoZ-CRO offers a broad range of professional services and partner solutions for international clinical studies with pharmaceuticals and medical devices.


From its head office located in Overath, Germany, AtoZ-CRO manages and coordinates clinical studies of phase 0 through phase IV for national and international clients. The company forms a team of 35 highly experienced and dedicated industry professionals and medical specialists ensuring high standards in clinical study management. AtoZ-CRO is affiliated with a leading initiator of phase I studies in Warsaw, Poland.


Based on the company’s long-established international experience in clinical trial management and cooperation with high-rated business partners, AtoZ-CRO is proud to offer a broad range of services covering all clinical research needs, in particular for small and mid-sized pharmaceutical, biotech, and medical device companies.

Clinical Studies 

Contact us

Clinical Studies

Clinical Studies Phases 0 – IV

  • Planning of clinical studies
  • Preparation of study protocols
  • Design and implementation of CRFs (case report forms) and eCRFs
  • Processing of applications for ethical votes and permissions (e.g. CTA, IND)
  • Regulatory affairs issues
  • Legal EU representative

Other services

  • Monitoring
  • Post-marketing studies

-  NIS

-  PASS

-  Epidemiology

  • Pharmacovigilance
  • Biometry
  • Medical Writing and Translations

About us

Contact us

Contact us

AtoZ-CRO GmbH

Hauptstr. 77
51491 Overath
Tel: 02206 95 99 0
Fax: 02206 820 63
Email: info@atoz-cro.de
www.atoz-cro.de

Business Development

Alexa Foltin-Mertgen, M.Sc.
Email: a.foltin-mertgen@atoz-cro.de

Back to top ⇧

Go to article: Home | The race to regulate 3D printed devicesGo to article: Formacoat Company InsightGo to article: FormacoatGo to article: In this issueGo to article: MPS Microsystems Company InsightGo to article: MPS MicrosystemsGo to article: ContentsGo to article: Micro Systems TechnologiesGo to article: Cap Biomaterials Company Insight Go to article: Cap BiomaterialsGo to article: NewsGo to article: MikronGo to article: Ide8Go to article: The medical industry briefingGo to article: Protomatic Company InsightGo to article: Protomatic MedicalGo to article: Automation vs AI in medtech: where are we headed?Go to article: Telemed Company InsightGo to article: TelemedGo to article: NSFGo to article: A breakthrough in 3D-printed neuronal stem cells and scaffold therapyGo to article: ElectroCraftGo to article: ElectroCraft Company InsightGo to article: Maxon MotorGo to article: Otsuka and Magellan Health collaborate to launch first digital pillGo to article: Bright PlasticsGo to article: ARPA Company InsightGo to article: ARPAGo to article: Nelson Labs Company InsightGo to article: Nelson LabsGo to article: Novartis aims to disrupt healthcare with ‘digital ecosystem’Go to article: Linemaster Company InsightGo to article: LinemasterGo to article: Performance Motion Devices Company InightGo to article: Performance Motion DevicesGo to article: Will FDA’s new guidance boost medical device cybersecurity?Go to article: Machine Solutions Company InsightGo to article: Machine SolutionsGo to article: AtoZ-CRO GmbHGo to article: AtoZ-CRO GmbH Company InsightGo to article: Transporting human organs: the innovations saving livesGo to article: Maraca InternationalGo to article: Accurate Biometrics Company InsightGo to article: Accurate BiometricsGo to article: Breaking point: should we be reusing more medical devices?Go to article: ABBGo to article: ABB Company InsightGo to article: 3D printed medical devices: a tough trial for regulation?Go to article: Ash TechnologiesGo to article: Innomech Company InsightGo to article: InnomechGo to article: Cutting complete blood count tests from days to minutesGo to article: Medica LLC Company InsightGo to article: Medica LLCGo to article: AberdeenGo to article: “At least I have my health”: the reputational impact of AI in healthcareGo to article: Freund ElectronicGo to article: myLiquitabGo to article: Amplifying the patient voice and the role of linguistic validationGo to article: Art of TechnologyGo to article: AerotechGo to article: Erdmann Design SwitzerlandGo to article: Human + machine: the future of digital healthcareGo to article: Velixx Company InsightGo to article: VelixxGo to article: EventsGo to article: Lubrizol LifeSciencesGo to article: CS Hyde CompanyGo to article: Next issue